CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Abeona Therapeutics Inc.  (ABEO)
Other Ticker:  
 
    Sector  Healthcare    Industry Major Pharmaceutical Preparations
 

Abeona Therapeutics's Quick Ratio

ABEO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:                        

ABEO Quick Ratio (Mar 31 2017)
I. Quarter
(Dec 31 2016)
IV. Quarter
(Sep 30 2016)
III. Quarter
(Jun 30 2016)
II. Quarter
(Mar 31 2016)
I. Quarter
Y / Y Current Liabilities Change -43.33 % 190.86 % 60.19 % 145.16 % 193.87 %
Y / Y Cash & cash equivalent Change 69.04 % 72.26 % -27.95 % 12.8 % 370.5 %
Quick Ratio MRQ 30.61 16.09 12.4 7.29 10.26
Overall Ranking # 71 # 158 # 223 # 416 # 314
Seq. Current Liabilities Change -51.93 % 70.82 % -46.57 % 29.17 % 146.72 %
Seq. Cash & cash equivalent Change -8.58 % 121.72 % -9.09 % -8.27 % -6.83 %



Quick Ratio first quarter 2017 Comment
Current Liabilities decreased faster than Abeona Therapeutics's Cash & cash equivalent, this led to improvement in Abeona Therapeutics's Quick Ratio to 30.61, Quick Ratio remained below Abeona Therapeutics Inc. average.

Within Major Pharmaceutical Preparations industry 3 other companies have achieved higher Quick Ratio than Abeona Therapeutics in first quarter 2017. While Quick Ratio total ranking has improved so far to 71, from total ranking in previous quarter at 158.

Explain Quick Ratio?
What are ABEO Segments?
See Quick Ratio ABEO on the trailing twelve month basis
Quick Ratio first quarter 2017 Company Ranking
Within: No.
Industry # 4
Sector # 10
S&P 500 # 71


Quick Ratio Statistics
High Average Low
30.61 7.21 0
(Mar 31 2017)   (Jun 30 2014)


You need to upgrade your Flash Player


Financial Statements
Abeona Therapeutics's Current Liabilities $ 2 Millions Visit ABEO's Balance sheet
Abeona Therapeutics's Cash & cash equivalent $ 63 Millions Visit ABEO's Balance sheet
Source of ABEO's Sales Visit ABEO's Sales by Geography




Companies with similar Quick Ratio in the quarter endingMar 31 2017, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2017 MRQ Cash & cash equivalentMar 31 2017 MRQ Current Liabilities
Flex Pharma, Inc.  58.23 $ 52.815  Millions$ 0.907  Millions
Corvus Pharmaceuticals, Inc.  50.42 $ 122.064  Millions$ 2.421  Millions
Prothena Corp Plc  42.32 $ 506.550  Millions$ 11.970  Millions
Abeona Therapeutics Inc.  30.61 $ 63.212  Millions$ 2.065  Millions
Syros Pharmaceuticals, Inc.  27.67 $ 70.494  Millions$ 2.548  Millions
Dipexium Pharmaceuticals, Inc.  26.98 $ 12.471  Millions$ 0.462  Millions
Endocyte Inc  25.95 $ 127.562  Millions$ 4.915  Millions
Aimmune Therapeutics, Inc.  24.09 $ 246.247  Millions$ 10.223  Millions
Sierra Oncology, Inc.  23.94 $ 125.025  Millions$ 5.222  Millions
Loxo Oncology, Inc.  23.09 $ 240.315  Millions$ 10.408  Millions
Kindred Biosciences, Inc.  22.88 $ 65.138  Millions$ 2.847  Millions
Sophiris Bio Inc.  22.84 $ 25.694  Millions$ 1.125  Millions
Intra-cellular Therapies, Inc.  22.54 $ 367.781  Millions$ 16.319  Millions
Inotek Pharmaceuticals Corporation  21.77 $ 114.705  Millions$ 5.268  Millions
Medicinova Inc  21.17 $ 21.637  Millions$ 1.022  Millions
Aquinox Pharmaceuticals, Inc  20.88 $ 121.581  Millions$ 5.824  Millions
Ra Pharmaceuticals, Inc.  19.86 $ 105.373  Millions$ 5.307  Millions
Pain Therapeutics Inc  19.55 $ 17.264  Millions$ 0.883  Millions
Dermira, Inc.  19.46 $ 414.627  Millions$ 21.311  Millions
Enanta Pharmaceuticals Inc  19.18 $ 175.573  Millions$ 9.154  Millions
Catalyst Pharmaceuticals, Inc.  19.17 $ 36.527  Millions$ 1.906  Millions
Chimerix Inc  18.73 $ 161.695  Millions$ 8.632  Millions
Biospecifics Technologies Corp  18.39 $ 47.872  Millions$ 2.603  Millions
Otonomy, Inc.  17.90 $ 168.124  Millions$ 9.390  Millions
Global Blood Therapeutics, Inc.  16.57 $ 244.324  Millions$ 14.747  Millions
Scynexis Inc  16.35 $ 54.899  Millions$ 3.358  Millions
Xenon Pharmaceuticals Inc.  16.16 $ 58.027  Millions$ 3.591  Millions
Kura Oncology, Inc.  16.04 $ 59.153  Millions$ 3.688  Millions
Aduro Biotech, Inc.  14.76 $ 353.961  Millions$ 23.975  Millions
Aeglea Biotherapeutics, Inc.  14.62 $ 57.868  Millions$ 3.957  Millions
Economy

Advance Monthly Sales
Consumer Price Index CPI
Producer Price Index PPI
Retail Inventories
Personal Income
Gross Domestic Product GDP
Money Supply
Industrial Production
Productivity
Employment Situation
US International Trade
Factory Orders
Durable Goods
Construction Spending
Housing Starts
Vehicle Unit Sales
Stocks

Event Calendar
BTLN's Profile
Stock Price
BTLN's Financials
BTLN's Expectations
Business Description
Fundamentals
Charts & Quotes
BTLN's News
Suppliers
BTLN's Competitors
Customers & Markets
Economic Indicators
BTLN's Growth
Company Segments
Industries

At a Glance
Performance
Growth Rates
Profitability
Valuation
Financial Strength
Markets

At a Glance
Stocks
Indices
Sectors & Industries
Financials
Commodities
Currencies
Screening

Stock Performance
Growth Rates
Profitability
Valuation
Dividend
Financial Strength
Efficiency
Expectations
Management Effectivness
News

At a Glance
Stocks
Economy
Industries
Other
Glossary

Financial Terms
Technical Analysis
Fundamental Analysis
Energy Terms
Manufacturing Terms
Transportation Terms
Health Care
Insurance Terms
Economy Terms
Hotel & Leisure Terms
Help

Sitemap
Advertise
About us
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2017 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com